Valuation Survey for SF-6Dv2 in Japan Based on the International Protocol

Overview

Journal Qual Life Res

Specialties Pharmacology
Rehabilitation Medicine

Date 2024 Nov 27

PMID 39602017

Authors

Takeru Shiroiwa

Yosuke Yamamoto

Tatsunori Murata

Brendan Mulhern

Jakob Bjorner

John Brazier

Takashi Fukuda

Donna Rowen

Shun-Ichi Fukuhara

Affiliations

Soon will be listed here.

Abstract

Purpose: The SF-6D Classification System was recently updated (SF-6Dv2). We performed a valuation survey to construct a value set for the SF-6Dv2 in Japan.

Methods: An online discrete choice experiment (DCE) with duration was used to estimate a value set for the SF-6Dv2 for Japan based on public preferences. The target sample number was 3800. Respondents were asked to complete 15 choice tasks. A conditional logit model that estimates interactions between time and each dimension was used to develop the value set.

Results: The collected sample included 3933 respondents for the DCE tasks. The results of all the unconstrained models showed some inconsistencies. In particular, inconsistencies in the two most severe levels of the role limitation (RL) and vitality (VT) dimensions were observed in all models. The number of inconsistencies was smallest in a core model (n = 3) and in a model for core and common health states (n = 2). The physical functioning (PF) and pain (PA) dimensions had the greatest influence on utility at the overall level across all models. RL, VT, and social functioning (SF) had smaller overall impacts on utility. The PF weights for the two most severe levels are much lower than those in the UK and Australia. The Japanese scores tended to be lower compared with the UK SF-6Dv2 scores.

Conclusion: We obtained a value set for Japan (model 5). With the development of this value set, it is now possible to calculate quality-adjusted life years for economic evaluation in Japan when the SF-6Dv2 has been used.

Citing Articles

Health utility scores of six common cancers in China measured by SF-6Dv2.

Tao Y, Cao Y, Xu L, Shi J, Leng L, Yang H Health Qual Life Outcomes. 2025; 23(1):5.

PMID: 39799326 PMC: 11725192. DOI: 10.1186/s12955-025-02332-8.

References

Shiroiwa T, Ikeda S, Noto S, Fukuda T, Stolk E . Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan. Med Decis Making. 2021; 41(5):597-606. PMC: 8191148. DOI: 10.1177/0272989X211001859. View

Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T . Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002; 11(4):341-53. DOI: 10.1002/hec.673. View

Norman R, Viney R, Brazier J, Burgess L, Cronin P, King M . Valuing SF-6D Health States Using a Discrete Choice Experiment. Med Decis Making. 2013; 34(6):773-86. DOI: 10.1177/0272989X13503499. View

King M, Norman R, Mercieca-Bebber R, Costa D, McTaggart-Cowan H, Peacock S . The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. Value Health. 2021; 24(6):862-873. DOI: 10.1016/j.jval.2021.01.007. View

Brazier J, Usherwood T, Harper R, Thomas K . Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998; 51(11):1115-28. DOI: 10.1016/s0895-4356(98)00103-6. View

Shiroiwa T, Nakamura-Thomas H, Yamaguchi M, Morikawa M, Moriyama Y, Fukuda T . Japanese preference weights of the Adult Social Care Outcomes Toolkit for Carers (ASCOT-Carer). Qual Life Res. 2022; 31(7):2143-2151. PMC: 8752387. DOI: 10.1007/s11136-021-03076-w. View

Noto S, Shiroiwa T, Kobayashi M, Murata T, Ikeda S, Fukuda T . Development of a multiplicative, multi-attribute utility function and eight single-attribute utility functions for the Health Utilities Index Mark 3 in Japan. J Patient Rep Outcomes. 2020; 4(1):23. PMC: 7125285. DOI: 10.1186/s41687-020-00188-8. View

Konomura K, Numakura C, Nakamura-Utsunomiya A, Hoshino E, Tajima G, Kobayashi H . Health-related quality of life and caregiver burden of pediatric patients with inborn errors of metabolism in Japan using EQ-5D-Y, PedsQL, and J-ZBI. Qual Life Res. 2024; 33(12):3323-3333. PMC: 11599479. DOI: 10.1007/s11136-024-03775-0. View

Norman R, Mulhern B, Viney R . The Impact of Different DCE-Based Approaches When Anchoring Utility Scores. Pharmacoeconomics. 2016; 34(8):805-14. DOI: 10.1007/s40273-016-0399-7. View

Brazier J, Fukuhara S, Roberts J, Kharroubi S, Yamamoto Y, Ikeda S . Estimating a preference-based index from the Japanese SF-36. J Clin Epidemiol. 2009; 62(12):1323-31. DOI: 10.1016/j.jclinepi.2009.01.022. View

10.

Shiroiwa T, Fukuda T, Ikeda S, Igarashi A, Noto S, Saito S . Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life Res. 2015; 25(3):707-19. PMC: 4759213. DOI: 10.1007/s11136-015-1108-2. View

11.

Shiroiwa T, Moriyama Y, Nakamura-Thomas H, Morikawa M, Fukuda T, Batchelder L . Development of Japanese utility weights for the Adult Social Care Outcomes Toolkit (ASCOT) SCT4. Qual Life Res. 2019; 29(1):253-263. PMC: 6962125. DOI: 10.1007/s11136-019-02287-6. View

12.

Shiroiwa T, Noto S, Fukuda T . Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings. Value Health. 2021; 24(8):1193-1202. DOI: 10.1016/j.jval.2021.03.010. View

13.

Brazier J, Mulhern B, Bjorner J, Gandek B, Rowen D, Alonso J . Developing a New Version of the SF-6D Health State Classification System From the SF-36v2: SF-6Dv2. Med Care. 2020; 58(6):557-565. DOI: 10.1097/MLR.0000000000001325. View

14.

Mulhern B, Norman R, Brazier J . Valuing SF-6Dv2 in Australia Using an International Protocol. Pharmacoeconomics. 2021; 39(10):1151-1162. DOI: 10.1007/s40273-021-01043-4. View

15.

Devlin N, Shah K, Feng Y, Mulhern B, van Hout B . Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ. 2017; 27(1):7-22. PMC: 6680214. DOI: 10.1002/hec.3564. View

16.

Xie S, Wu J, Chen G . Discrete choice experiment with duration versus time trade-off: a comparison of test-retest reliability of health utility elicitation approaches in SF-6Dv2 valuation. Qual Life Res. 2022; 31(9):2791-2803. DOI: 10.1007/s11136-022-03159-2. View

17.

Shiroiwa T . Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in Japan. Int J Technol Assess Health Care. 2020; 36(3):270-276. DOI: 10.1017/S0266462320000264. View

18.

King M, Viney R, Pickard A, Rowen D, Aaronson N, Brazier J . Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30. Pharmacoeconomics. 2017; 36(2):225-238. PMC: 5805814. DOI: 10.1007/s40273-017-0582-5. View

19.

Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S . Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan. Value Health. 2016; 19(5):648-54. DOI: 10.1016/j.jval.2016.03.1834. View